new oversight of pharmacy compounding

December 2012

The fungal meningitis outbreak will result in new oversight of pharmacy compounding.

We all know that compounding fills several important needs. Up to 3% of all prescriptions are compounded by community pharmacies, hospitals, etc.

But it gets confusing when a compounder acts like a manufacturer.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cardiology whether ALL patients with coronary artery disease should take a beta-blocker
Anticoagulants Xarelto (rivaroxaban) will be used to TREAT venous thromboembolism
Anticoagulants more about bleeding with Pradaxa (dabigatran)
Gastroenterology Linzess (lin-ZESS, linaclotide) for irritable bowel syndrome with constipation or chronic constipation in adults
Corticosteroids Rayos, a new delayed-release prednisone designed for evening dosing
Vaccines Prevnar 13 vaccine will be used in certain ADULTS
Vaccines New CDC guidelines will bring more focus on proper vaccine storage
Diabetes debate about whether diabetes patients who don't use insulin benefit from monitoring their blood glucose
Respiratory & Allergy Tudorza Pressair (TU-door-za, aclidinium), a new inhaled bronchodilator for COPD
Gout rev up promotion of Uloric (febuxostat) for managing gout
Compounding new oversight of pharmacy compounding
Interactions PPIs with methotrexate can lead to methotrexate toxicity
Practice enjoy the holiday letter from our staff